Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 67-77

  Ascher Svanum, Haya ^a   Zhu, Baojin ^a   Faries, Douglas E ^a   Lacro, Jonathan P ^b   Dolder, Christian R ^c   Peng, Xiaomei ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WINGATE UNIVERSITY   (United States)

Author keywords

Adherence; Antipsychotics; Persistence; Schizophrenia

Indexed keywords

EID: 65649093241     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S2940     Document Type: Article

References (65)

1. Al-Zakwani IS, Barron JJ, Bullano MF, et al. 2003. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin, 19:619-26.
2. Ascher-Svanum H, Zhu B, Faries D, et al. 2004. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry, 3:11.
3. Ascher-Svanum H, Faries DE, Zhu B, et al. 2006a. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry, 67:453-60.
4. Ascher-Svanum H, Zhu B, Faries D, et al. 2006b. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry, 6:8.
5. Bagnall A. M, Jones L, Ginnelly L, et al. 2003. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess, 7:1-193. URL: http://www.ncchta.org/project.asp?PjtId 771235 Health Technology Assessment (HTA) on behalf of the National Institute for Clinical Excellence (NICE) in the UK.
6. Beasley C. M, Stauffer VL, Liu-Seifert H, et al. 2007. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol, 27:252-8.
7. Box G. EP, Cox DR. 1964. An analysis of transformations. Journal of the Royal Statistical Society, 26:211-43.
8. Breier A., Berg PH, Thakore JH, et al. 2005. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry, 162:1879-1887.
9. Cooper D., Moisan J, Gregoire JP. 2007. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry, 68:818-25.
10. Cramer J. A, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv, 49:196-201.
11. Davis J. M, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 60:553-64.
12. Diaz E., Neuse E, Sullivan MC, et al. 2004. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry, 65:354-360.
13. Dolder C. R, Lacro JP, Dunn LB, et al. 2002. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry, 159:103-8.
14. Dossenbach M., Erol A, el Mahfoud Kessaci M, et al. 2004. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry, 65:312-21.
15. Elbogen E. B, Swanson JW, Swartz MS, et al. 2005. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis, 193:673-9.
16. Faries D., Ascher-Svanum H, Zhu B, et al. 2005. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry, 5:26.
17. Fenton W. S, Blyler CR, Heinssen RK. 1997. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull, 23:637-51.
18. Garcia-Cabeza I, Gomez JC, Sacristan JA, et al. 2001. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry, 1:7.
19. Geddes J., Freemantle N, Harrison P, et al. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ, 321:1371-6.
20. Gianfrancesco F. D, Rajagopalan K, Sajatovic M, et al. 2006. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res, 144:177-89.
21. Gibson P. J, Damler R, Jackson EA, et al. 2004. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health, 7:22-35.
22. Gilbody S. M, Bagnall AM, Duggan L, et al. 2000. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochran Database Syst Rev, 3:CD002306.
23. Gilmer T. P, Dolder CR, Lacro JP, et al. 2004. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry, 161:692-9.
24. Glick I. D, Berg PH. 2002. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol, 17:65-8.
25. Haro J. M, Suarez D, Novick D, et al. 2007. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol, 17:235-44.
26. Jayaram M. B, Hosalli PM, Stroup TS. 2007. Risperidone versus olanzapine for treatment of schizophrenia. Schizophr Bull, 33:1274-6.
27. Jones P. B, Barnes TR, Davies L, et al. 2006. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63:1079-87.
28. Joyce A. T, Harrison DJ, Loebel AD, et al. 2005. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care, 11:S254-61.
29. Kampman O., Lehtinen K. 1999. Compliance in psychoses. Acta Psychiatr Scand, 100:167-75.
30. Kemmler G., Hummer M, Widschwendter C, et al. 2005. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry, 62:1305-12.
31. Kinon B. J, Lipkovich I, Edwards SB, et al. 2006a. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol, 26:157-62.
32. Kinon B. J, Noordsy DL, Liu-Seifert H, et al. 2006b. Randomized doubleblind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol, 26:453-61.
33. Leucht S., Barnes TR, Kissling W, et al. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry, 160:1209-22.
34. Lieberman J. A, Tollefson G, Tohen M, et al. 2003. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in firstepisode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry, 160:1396-404.
35. Lieberman J. A, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353:1209-23.
36. McEvoy JP, Lieberman JA, Stroup TS, et al. 2006. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163:600-10.
37. Menzin J., Boulanger L, Friedman M, et al. 2003. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv, 54:719-23.
38. Mojtabai R., Lavelle J, Gibson PJ, et al. 2003. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr Bull, 29:519-30.
39. Mudge N. AC, Davey PJ, Coleman KA, et al. 2005. A comparison of olanzapine versus risperidone for the treatment of schizophrenia-a meta analysis of randomized clinical trials. Int J Psychiatr Clin Pract, 9:3-15.
40. Mullins C. D, Obeidat NA, Cuffel BJ, et al. 2007. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res, [Epub ahead of print].
41. Opolka J. L, Rascati KL, Brown CM, et al. 2003. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother, 37:625-30.
42. Pelagotti F., Santarlasci B, Vacca F, et al. 2004. Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur J Clin Pharmacol, 59:905-9.
43. PhRMA clinicalstudyresults. org website. URL: http://www.clinicalstudyresults. org/documents/company-study_509_1.pdf Aripiprazole/BMS Clinical Study Report CN138003
44. Rascati K. L, Johnsrud MT, Crismon ML, et al. 2003. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics, 21:683-97.
45. Ren X. S, Kazis LE, Lee AF, et al. 2002. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J Clin Pharm Ther, 27:441-51.
46. Revicki D. A, Genduso LA, Hamilton SH, et al. 1999. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res, 8:417-26.
47. Rosenheck R., Perlick D, Bingham S, et al. 2003. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA, 290:2693-702.
48. Rosenheck R.A. 2005. Open forum: effectiveness versus efficacy of secondgeneration antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv, 56:85-92.
49. Rosenheck R. A, Leslie DL, Sindelar J, et al. 2006. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry, 163:2080-9.
50. Santarlasci B., Messori A. 2003. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother, 37:556-63.
51. Simpson G. M, Glick ID, Weiden PJ, et al. 2004. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry, 161:1837-47.
52. Søholm B., Lublin H. 2003. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand, 107:344-50.
53. Strom B. L, Faich G, Eng E, et al. 2007. Comparative Mortality Associated with Ziprasidone vs Olanzapine in Real-World Use: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Presented at the 46th annual meeting of the American College of Neuropsychopharmacology (ACNP), December 12, 2007, Boca Raton, FL.
54. Stroup T. S, McEvoy JP, Swartz MS, et al. 2003. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull, 29:15-31.
55. Stroup T. S, Lieberman JA, McEvoy JP, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 163:611-22.
56. Svarstad B. L, Shireman TI, Sweeney JK. 2001. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv, 52:805-11.
57. Swanson J. W, Swartz MS, Elbogen EB, et al. 2004a. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry, 65:1666-73.
58. Swanson J. W, Swartz MS, Elbogen EB. 2004b. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull, 30:3-20.
59. Thieda P., Beard S, Richter A, et al. 2003. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv, 54:508-16.
60. Tiihonen J., Walhbeck K, Lönnqvist J, et al. 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ, 333:224.
61. Tunis S. L, Faries DE, Nyhuis AW, et al. 2006. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health, 9:77-89.
62. Valenstein M., Copeland LA, Blow FC, et al. 2002. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care, 40:630-9.
63. Valenstein M., Blow FC, Copeland LA, et al. 2004. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull, 30:255-64.
64. Weiden P. J, Kozma C, Grogg A, et al. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv, 55:886-91.
65. Zhao Z., Tunis SL, Lage M. 2002. Mediation treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest, 22:741-9.